Abbott receives FDA approval for neurostimulator-controlling iPhone app, for personalizing therapies for pain, Parkinson's disease

Fiercebiotech, 24/07/2020

Partagé par : 

Équipe Beesens

Abbott receives FDA approval for neurostimulator-controlling iPhone app, for personalizing therapies for pain, Parkinson's disease

"The FDA approved a new smartphone app from Abbott allowing people to personalize their own neuromodulation therapies, including regimens for chronic pain and movement disorders such as Parkinson’s disease. Compatible with Apple products, the devicemaker’s NeuroSphere Digital Care platform and its newly approved patient controller app are also designed to encourage more virtual connections with healthcare providers, and allow interactions to take place remotely in the face of the COVID-19..." Lire la suite